The medical imaging device segment was one of the worst performing sectors in the healthcare industry during the second quarter of 1998, with earnings dropping 14.5% despite a revenue increase of 6.8%, according to a report produced by KPMG’s Health
The medical imaging device segment was one of the worst performing sectors in the healthcare industry during the second quarter of 1998, with earnings dropping 14.5% despite a revenue increase of 6.8%, according to a report produced by KPMGs Health Care Transaction Services division and WDI Healthcare Markets Group. Only the durable medical equipment and monitoring devices segments posted lower results, with earnings for those sectors dropping 28.2% and 36.8%, respectively.
For imaging device companies, the quarter continues a reduced profitability trend that has plagued the sector in recent periods. In the first quarter of this year, earnings decreased 1.9% with a 10.5% increase in revenue, according to KPMG and WDI, which is based in Hilton Head, SC. Fourth-quarter earnings were down 15.2% despite a 9.6% increase in revenue.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.